CAPN2 and colitis: A previous study has demonstrated the therapeutic potential of CAPN2 inhibitors in murine colitis and colitis-associated cancer, utilizing the azoxymethane/dextran sulfate sodium model to suppress macrophage activation and restrict tumor progression 53.